Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Goodwin Completes Areva Conjugate Mfg. | Contract Pharma

What are you searching for?

Sign in
Breaking News

Goodwin Completes Areva Conjugate Mfg.

Goodwin Biotechnology Inc. has completed the cGMP manufacturing and vialing of Areva Med's MAb-chelator conjugate

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Goodwin Biotechnology Inc. (GBI) has completed the cGMP manufacturing and vialing of Areva Med’s monoclonal antibody-chelator conjugate. As part of Areva Med’s Lead-212 (212Pb) initiative, the conjugate will be used in Phase I clinical trials to treat several types of deadly forms of cancers.

David Fischer, executive vice president of GBI, said, “We are very pleased to have completed the manufacturing of AREVA Med’s conjugate. After some promising preclinical data, we look forward to seeing the outcome of the first-in-man studies.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics